Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

PURPOSE: New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for alemtuzumab treatment; these groups have poor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Wierda, William G., Kipps, Thomas J., Mayer, Jiří, Stilgenbauer, Stephan, Williams, Cathy D., Hellmann, Andrzej, Robak, Tadeusz, Furman, Richard R., Hillmen, Peter, Trneny, Marek, Dyer, Martin J.S., Padmanabhan, Swami, Piotrowska, Magdalena, Kozak, Tomas, Chan, Geoffrey, Davis, Randy, Losic, Nedjad, Wilms, Joris, Russell, Charlotte A., Österborg, Anders
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2010
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979101/
https://ncbi.nlm.nih.gov/pubmed/20194866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.3187
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items